# acute kidney injury FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/acute-kidney-injury

> 1 upcoming FDA catalyst in acute kidney injury: CalciMedica, Inc. (CALC) on December 31, 2026 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for acute kidney injury?

1 upcoming FDA catalyst in acute kidney injury: CalciMedica, Inc. (CALC) on December 31, 2026 (topline data readout). SEC Form 10-Q: "Warrants were exercisable immediately upon issuance and will expire upon the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) 30 days following the Company's public disclosure of topline results from a Phase 2 clinical trial in patients with acute kidney injury." [Calendar and source filings](https://sec-api.dev/indications/acute-kidney-injury)

Source: SEC Form 10-Q, accession 0001193125-26-455490, https://www.sec.gov/Archives/edgar/data/1534133/000119312526455490/ck0001534133-20260930.htm (retrieved 2026-11-12). Last confirmed 2026-11-10. Cite: https://sec-api.dev/indications/acute-kidney-injury#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jan 2026 | [CM5480 trial start](https://sec-api.dev/pdufa/cm5480) | CALC | acute kidney injury | completed | "The Company initiated a Phase 2 trial (KOURAGE; NCT06374797) evaluating Auxora in patients with acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF); in January 2026, CalciMedica paused enrollment in the trial following a recommendation from the Independent Data Monitoring Committee and, as a next step, plans to discuss potential future development in AKI with the FDA." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534133/000119312526218134/ck0001534133-ex99_1.htm)) |
| April 6, 2026 | [Auxora primary completion](https://sec-api.dev/pdufa/auxora) | CALC | Acute Kidney Injury | withdrawn | "NCT06374797 (A Study of Auxora in Patients With AKI and Injurious Lung "Crosstalk"): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-04-06 (ACTUAL); Lead Sponsor CalciMedica, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06374797)) |
| December 31, 2026 | [CalciMedica, Inc. topline data readout](https://sec-api.dev/companies/calc/catalysts) | CALC | acute kidney injury | scheduled | "Warrants were exercisable immediately upon issuance and will expire upon the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) 30 days following the Company's public disclosure of topline results from a Phase 2 clinical trial in patients with acute kidney injury." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1534133/000119312526455490/ck0001534133-20260930.htm)) |

## Drugs

- [CM5480](https://sec-api.dev/pdufa/cm5480) (CALC)
- [Auxora](https://sec-api.dev/pdufa/auxora) (CALC)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/acute-kidney-injury.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "acute kidney injury FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/acute-kidney-injury

```bibtex
@misc{secapidev_indications_acute_kidney_injury_20261116,
  title        = {acute kidney injury FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/acute-kidney-injury}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_acute_kidney_injury_20261116","title":"acute kidney injury FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/acute-kidney-injury","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
